Mustang Bio Inc. Common Stock (MBIO)

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination M…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

4

Website

www.mustangbio.com/

Fundamentals

1-day range

$0.5328$0.55

Market cap

$3.88M

P/E (trailing)

—

P/E (forward)

-1.54

EPS (trailing)

$-0.49

Dividend yield

—

Beta

2.08

Avg. volume

127.5K

Mustang Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MBIO

  Mustang Bio Inc. Common Stock

  $0.5375

  ▼ 2.27%
  Market cap $3.88MP/E —
  $0.525$1.85
• RDHL

  Redhill Biopharma Ltd. American Depositary Shares

  $0.6899

  ▲ 9.51%
  Market cap $3.95MP/E —
  $0.57$2.79
• REVB

  Revelation Biosciences Inc. Common Stock

  $1.05

  ▲ 1.94%
  Market cap $3.99MP/E 0.04
  $0.875$11.6
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $4.57

  ▼ 4.99%
  Market cap $4.02MP/E —
  $3.18$71.5
• XRTX

  XORTX Therapeutics Inc. Common Shares

  $2.34

  ▼ 4.18%
  Market cap $3.69MP/E —
  $2.42$9.85
• PPCB

  Propanc Biopharma Inc. Common Stock

  $1.4

  ▼ 37.22%
  Market cap $3.68MP/E —
  $0.95$85.5
• INM

  InMed Pharmaceuticals Inc. Common Shares

  $1.43

  ▼ 0.35%
  Market cap $4.09MP/E —
  $0.575$2.5

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

475.9K

Total value held

$346.5K

Institutional holders

20